Cartesian Therapeutics (RNAC) Net Income towards Common Stockholders (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$26.6 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 31.95% year-over-year to -$26.6 million in Q1 2026; TTM through Mar 2026 was -$113.2 million, a 71.41% decrease from a year earlier, with the FY2025 full-year figure at -$130.3 million, down 68.26% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$26.6 million, up from -$75.2 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for RNAC reached as high as $13.4 million in Q2 2022 and fell as low as -$196.7 million in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged -$24.6 million across 5 years, with a median of -$19.2 million in 2023.
• Across the five-year window, Net Income towards Common Stockholders surged 5275.19% in 2022 and sank 3437.15% in 2023, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at $5.9 million in 2022, then sank by 3437.15% to -$196.7 million in 2023, then jumped by 87.14% to -$25.3 million in 2024, then tumbled by 197.55% to -$75.2 million in 2025, then soared by 64.59% to -$26.6 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$26.6 million in Q1 2026, -$75.2 million in Q4 2025, and -$24.6 million in Q3 2025.